Cardiovascular Disease Risk Assessment – A new approach using AI

By Michael Awood

September 20, 2023

Artificial intelligence (AI) has a far reaching grasp. It continues to extend its reach into the healthcare space. One of the areas that its having a profound impact is in the space of early disease detection. Its now changing the way we predict and manage cardiovascular disease (CVD), which is a leading cause of mortality worldwide. Traditional risk factors such as age, sex, and family history are combined with clinical parameters like glucose and cholesterol levels to calculate risk, but these methods fall short in assessing vascular condition directly and efficiently.

AI has paved the way for a more cost-effective tool for CVD risk assessment: ocular imaging. The eye’s microvascular system, particularly the retinal part, shares similarities with the brain and cardiovascular system. Research has shown a strong correlation between the retina and CVD. AI has been used to detect ocular diseases, and now, it is being applied to predict CVD from ocular images.

Despite these advancements, challenges remain showing significant limitations due to population variability. The limited availability of high-quality labelled data for AI model training and validation is also major issue. There is also a need for prospective trials to validate the model’s usefulness and safety in real-world scenarios.

The successful transition of AI-ocular image analysis from theory to real-world application requires addressing various challenges, including conducting cost-benefit analyses of AI models, securing funding sources, establishing information technology infrastructure, fostering social acceptance, managing clinical workflow changes, and navigating regulatory issues.

In conclusion, AI in ocular imaging offers a promising tool for CVD risk assessment. However, further research and collaboration are needed to address the challenges and bring this tool to clinical application. 



Reference url

Recent Posts

340B Drug Pricing Lawsuit
      

Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA

🤔 How will ongoing legal battles shape the future of the 340B Drug Pricing Program?

Eli Lilly and Johnson & Johnson are challenging HRSA’s proposed rebate models, arguing that their approaches are essential for enhancing transparency and ensuring discounts directly benefit vulnerable patients. This crucial legal dispute highlights the tensions surrounding drug pricing regulations and could profoundly impact how discounts are provided to covered entities.

Dive into the details of these lawsuits and their implications for the pharmaceutical landscape.

#SyenzaNews #pharmaceuticals #healthcarepolicy #innovation #DrugPricing

WHO Investment Round 2023
    

WHO Investment Round: Securing Funding with Transparency Challenges

🌍 How can global health initiatives thrive with increased funding?

The WHO Investment Round is a pivotal initiative striving to secure $7.1 billion for essential health programs from 2025 to 2028. While achieving 53% of this target via diverse donor engagement, transparency in funding remains a challenge. Discover how these efforts can accelerate progress towards universal health coverage and tackle critical health issues like malaria and cervical cancer!

#SyenzaNews #globalhealth #universalhealthcoverage #healthcare #innovation

HPV vaccination South Africa
    

HPV vaccination South Africa: Cervical Cancer Prevention

🌍 How is South Africa leading the charge against cervical cancer?

Since launching its HPV vaccination program, the country has made remarkable strides in protecting future generations. With impressive coverage rates and a focus on at-risk populations, South Africa serves as a global model for effective public health strategies. Discover how this initiative not only combats cervical cancer but also addresses broader health concerns.

#SyenzaNews #HealthTech #GlobalHealth #HealthcareInnovation #CervicalCancer #HPVVaccination

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.